Literature DB >> 3086065

Alfentanil in anesthesia and analgesia.

J A Reitz.   

Abstract

Alfentanil is a tetrazole derivative of fentanyl. Many of the pharmacologic effects of alfentanil are similar to those of fentanyl and sufentanil, but of quicker onset than those of fentanyl and of shorter duration than those of fentanyl and sufentanil. Alfentanil may cause less intense respiratory depression than equianalgesic doses of fentanyl. Alfentanil has a lower total body clearance, smaller volume of distribution, and shorter half-life than fentanyl and sufentanil. Clinical trials indicate alfentanil can be used effectively as an analgesic, an analgesic supplement to anesthesia, an anesthetic induction agent, and as the major component of a general anesthetic. Its short duration of effect makes it attractive as an analgesic supplement for short ambulatory surgical procedures. Alfentanil is recommended for addition to drug formularies, but its use should be restricted to anesthesia personnel.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086065     DOI: 10.1177/106002808602000501

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial.

Authors:  Nan Zhao; Jie Zeng; Lin Fan; Chao Zhang; YuJia Wu; Xin Wang; Feng Gao; Cong Yu
Journal:  Paediatr Drugs       Date:  2022-06-13       Impact factor: 3.930

Review 2.  Alfentanil infusions in patients requiring intensive care.

Authors:  A Bodenham; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Hypotensive anesthesia versus normotensive anesthesia during major maxillofacial surgery: a review of the literature.

Authors:  Michal Barak; Leiser Yoav; Imad Abu el-Naaj
Journal:  ScientificWorldJournal       Date:  2015-02-23

4.  Alfentanil and propofol induced anesthesia for patients with huge endotracheal tumor undergoing fiberoptic bronchoscopic interventional therapy: case report.

Authors:  Hongyu Zhu; Yan Sun; Tingting Wang; Zhilin Wu
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.